{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:15:50Z","timestamp":1783617350379,"version":"3.55.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"27","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,3]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>This study aimed to characterize the clinical profile of severe allergic reactions associated with rituximab therapy. We conducted a descriptive, retrospective analysis of published case reports and case series. Relevant reports published between January 2000 and October 2025 were identified through searches of PubMed, Embase, China National Knowledge Infrastructure, Chinese Science and Technology Journal Database, and WanFang databases. Data on patient demographics, clinical presentation, management, and outcomes were extracted and analyzed descriptively. A total of 24 documented cases were included. Patients had a mean age of 46.4 years, with a range of 6 to 86 years. Females accounted for 54.2% of the cases. The most frequent underlying condition was hematological malignancy, reported in 58.3% of patients. The majority of allergic reactions occurred within 24 hours of infusion, and nearly half occurred during the initial administration. Notably, in the included cases, 75.0% of patients developed severe reactions despite the administration of standard premedication. Predominant symptoms were dyspnea (37.5%), chest tightness (29.2%), laryngeal edema (25.0%), chills (20.8%), and hypotension (16.7%). According to the World Allergy Organization criteria, 75.0% of the cases met the diagnostic criteria for anaphylaxis. Primary management strategies included discontinuation of rituximab (79.2%), corticosteroids (54.1%), epinephrine (37.5%), and antihistamines (37.5%). While most patients (83.3%) improved following intervention, 20.8% required care in an intensive care unit or emergency department. Causality assessment using the Naranjo scale rated the association as \u201cprobable\u201d in 58.3% of cases and \u201ccertain\u201d in 25.0%. Rituximab can induce severe and potentially life-threatening allergic reactions. These reactions may occur in patients of any age, during any treatment cycle, and even after prophylactic medication has been administered. Most reactions are acute in onset and primarily involve the respiratory and cardiovascular systems. These findings highlight the importance of close monitoring and prompt intervention during rituximab therapy. Further studies are needed to refine preventive and management strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049513","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:01:44Z","timestamp":1783098104000},"page":"e49513","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A descriptive analysis of published case reports of severe allergic reactions induced by rituximab"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6306-2064","authenticated-orcid":false,"given":"Lijialong","family":"Yuan","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Hunan University of Medicine General Hospital, Huaihua, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, People\u2019s Hospital of Chenxi, Huaihua, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Hunan University of Medicine General Hospital, Huaihua, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronghui","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Hunan University of Medicine General Hospital, Huaihua, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of General Practice, Hunan University of Medicine General Hospital, Huaihua, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Hunan University of Medicine General Hospital, Huaihua, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5820-0123","authenticated-orcid":false,"given":"Yueping","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Hunan University of Medicine General Hospital, Huaihua, Hunan, China"},{"name":"Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260709","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdg175","article-title":"An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.","volume":"14","author":"Boye","year":"2003","journal-title":"Ann Oncol"},{"key":"R2-20260709","doi-asserted-by":"crossref","first-page":"100472","DOI":"10.1016\/j.waojou.2020.100472","article-title":"World Allergy Organization Anaphylaxis Guidance 2020.","volume":"13","author":"Cardona","year":"2020","journal-title":"World Allergy Organ J"},{"key":"R3-20260709","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/ijd.17311","article-title":"Rapid desensitization in a patient with pemphigus vulgaris and rituximab-induced anaphylaxis.","volume":"64","author":"Medeiros da Nobrega","year":"2025","journal-title":"Int J Dermatol"},{"key":"R4-20260709","doi-asserted-by":"crossref","first-page":"884","DOI":"10.24953\/turkjped.2020.05.025","article-title":"Rituximab-induced serum sickness and anaphylaxis in a child with nephrotic syndrome.","volume":"62","author":"Bayram","year":"2020","journal-title":"Turk J Pediatr"},{"key":"R5-20260709","first-page":"e38333","article-title":"Rituximab-induced serum sickness overlapping with anaphylaxis: a case report.","volume":"15","author":"Cottu","year":"2023","journal-title":"Cureus"},{"key":"R6-20260709","first-page":"77","article-title":"A case study of rituximab-induced anaphylactic shock in a child with nephrotic syndrome.","volume":"45","author":"Shi","year":"2024","journal-title":"Shanghai Med J"},{"key":"R7-20260709","first-page":"1325","article-title":"Rituximab-induced anaphylactic shock in the treatment of chronic lymphocytic leukemia: a case report.","volume":"33","author":"Peng","year":"2014","journal-title":"Herald Med"},{"key":"R8-20260709","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.anai.2019.03.008","article-title":"Rituximab hypersensitivity and desensitization: a personalized approach to treat cancer and connective tissue diseases.","volume":"123","author":"Yang","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R9-20260709","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jdcr.2021.08.005","article-title":"Pemphigus vulgaris successfully treated with ocrelizumab following rituximab allergy.","volume":"16","author":"Benesh","year":"2021","journal-title":"JAAD Case Rep"},{"key":"R10-20260709","first-page":"920","article-title":"Severe pemphigus vulgaris resistant to conventional therapies and with hypersensitivity to rituximab in a 12-year-old child.","volume":"10","author":"De Felici Del Giudice","year":"2023","journal-title":"Children (Basel, Switzerland)"},{"key":"R11-20260709","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13223-020-00448-8","article-title":"Type I allergic reaction to rituximab upon first lifetime exposure: a case report.","volume":"16","author":"Polito","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"R12-20260709","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000163069","article-title":"Rituximab-induced hypersensitivity pneumonitis.","volume":"78","author":"Tonelli","year":"2009","journal-title":"Respiration"},{"issue":"Suppl 1","key":"R13-20260709","first-page":"e2021115","article-title":"Hypertensive crisis and pulmonary edema following rituximab-induced anaphylaxis.","volume":"92","author":"Brili","year":"2021","journal-title":"Acta Biomed"},{"key":"R14-20260709","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/annonc\/mdg488","article-title":"Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment.","volume":"14","author":"Hellerstedt","year":"2003","journal-title":"Ann Oncol"},{"key":"R15-20260709","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.anai.2024.04.011","article-title":"Protracted anaphylaxis and cytokine release syndrome 6 days after rituximab desensitization.","volume":"133","author":"Finkel","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R16-20260709","first-page":"176","article-title":"Nursing management of laryngeal edema induced by rituximab therapy for diffuse large B cell lymphoma: with a case report.","volume":"4","author":"Chen","year":"2018","journal-title":"Nurs Integr Trad Chin Western Med"},{"key":"R17-20260709","first-page":"282","article-title":"Nursing care of allergic reactions induced by rituximab: two case reports.","volume":"18","author":"Wang","year":"2010","journal-title":"Tianjin Nurs J"},{"key":"R18-20260709","first-page":"90","article-title":"Grade 3 allergic reaction after repeated use of rituximab: a case report.","volume":"19","author":"Liang","year":"2021","journal-title":"Clin Med J"},{"key":"R19-20260709","first-page":"47","article-title":"Severe acute allergic reaction induced by repeated use of rituximab: a case report.","volume":"29","author":"Fang","year":"2022","journal-title":"Chin J Rural Med Pharm"},{"key":"R20-20260709","first-page":"361","article-title":"Rescue and nursing care of allergic reaction induced by rituximab: a case report.","volume":"14","author":"Ha","year":"2012","journal-title":"Chin Community Dr"},{"key":"R21-20260709","first-page":"504","article-title":"One case of allergic reaction and paroxysmal supraventricular tachycardia induced by rituximab injection.","volume":"16","author":"Li","year":"2019","journal-title":"Chin J Pharmacovigilance"},{"key":"R22-20260709","first-page":"101","article-title":"Nursing care of an allergic reaction during rituximab treatment for acute lymphoblastic leukemia: a case report.","volume":"38","author":"Xu","year":"2023","journal-title":"J Nurs Sci"},{"key":"R23-20260709","first-page":"343","article-title":"Rituximab allergy: report of one case.","volume":"28","author":"Tao","year":"2015","journal-title":"Med Inf"},{"key":"R24-20260709","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2021-149829","article-title":"Incidence and characteristics of CD20 monoclonal antibody-induced interstitial pneumonitis.","volume":"138","author":"Stein","year":"2021","journal-title":"Blood"},{"key":"R25-20260709","doi-asserted-by":"crossref","first-page":"100066","DOI":"10.1016\/j.waojou.2019.100066","article-title":"Time to revisit the definition and clinical criteria for anaphylaxis?","volume":"12","author":"Turner","year":"2019","journal-title":"World Allergy Organ J"},{"key":"R26-20260709","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40262-021-01081-3","article-title":"The influence of underlying disease on rituximab pharmacokinetics may be explained by target-mediated drug disposition.","volume":"61","author":"Bensalem","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"R27-20260709","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1182\/blood-2023-182055","article-title":"Severe reaction to rituximab in children.","volume":"142","author":"Feltesse","year":"2023","journal-title":"Blood"},{"key":"R28-20260709","doi-asserted-by":"crossref","first-page":"x313","DOI":"10.1093\/annonc\/mds314","article-title":"Prevention and handling of acute allergic and infusion reactions in oncology.","volume":"23","author":"Joerger","year":"2012","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"R29-20260709","doi-asserted-by":"crossref","first-page":"e19148","DOI":"10.1200\/JCO.2020.38.15_suppl.e19148","article-title":"Utilizing a novel four-drug regimen to reduce the incidence of infusion-related reactions for first-dose rituximab infusions: an institutional review of rituximab infusion-related reactions in lymphoma patients.","volume":"38","author":"Bartels","year":"2020","journal-title":"J Clin Oncol"},{"key":"R30-20260709","doi-asserted-by":"crossref","first-page":"572863","DOI":"10.3389\/fphar.2020.572863","article-title":"Rituximab hypersensitivity: from clinical presentation to management.","volume":"11","author":"Fouda","year":"2020","journal-title":"Front Pharmacol"},{"key":"R31-20260709","first-page":"43","article-title":"Incidence and influencing factors of rituximab-related hypersensitivity in inpatients: a case-control study.","volume":"20","author":"Siyuan","year":"2020","journal-title":"Pharm Educ"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000049513","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:01:40Z","timestamp":1783616500000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000049513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":31,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049513","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"2026-03-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}